{"disease":{"id":"gastroesophageal-junction-carcinoma","name":"gastroesophageal junction carcinoma"},"drugs":{"marketed":[{"drug_id":"trastuzumab-deruxtecan","indication_name":"Advanced HER2positive gastric or gastroesophageal junction (GEJ) adenocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Enhertu","generic_name":"trastuzumab-deruxtecan","company_name":"Daiichi Sankyo","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"","quality_score":63,"revenue":"2900","mechanism":"Enhertu works by binding to the HER2 protein and releasing a cytotoxic payload to kill cancer cells."},{"drug_id":"tislelizumab","indication_name":"Unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tevimbra","generic_name":"TISLELIZUMAB","company_name":"Beigene","drug_phase":"marketed","molecular_target":"Pd-1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"900","mechanism":"Tevimbra blocks the PD-1 receptor, allowing the immune system to recognize and attack cancer cells."},{"drug_id":"tislelizumab","indication_name":"Gastric or gastroesophageal junction adenocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tevimbra","generic_name":"TISLELIZUMAB","company_name":"Beigene","drug_phase":"marketed","molecular_target":"Pd-1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"900","mechanism":"Tevimbra blocks the PD-1 receptor, allowing the immune system to recognize and attack cancer cells."},{"drug_id":"zolbetuximab","indication_name":"locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyloy","generic_name":"ZOLBETUXIMAB","company_name":"Astellas","drug_phase":"marketed","molecular_target":"","drug_class":"Claudin 18.2-directed Cytolytic Antibody [EPC]","quality_score":55,"revenue":"100","mechanism":"Vyloy works by binding to Claudin 18.2 on cancer cells, triggering their destruction."},{"drug_id":"zolbetuximab","indication_name":"locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction adenocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyloy","generic_name":"ZOLBETUXIMAB","company_name":"Astellas","drug_phase":"marketed","molecular_target":"","drug_class":"Claudin 18.2-directed Cytolytic Antibody [EPC]","quality_score":55,"revenue":"100","mechanism":"Vyloy works by binding to Claudin 18.2 on cancer cells, triggering their destruction."},{"drug_id":"disitamab-vedotin","indication_name":"Locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Disitamab vedotin","generic_name":"disitamab-vedotin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"human epidermal growth factor receptor 2 (HER2)","drug_class":"antibody-drug conjugate","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"enhertu","indication_name":"Advanced HER2positive gastric or gastroesophageal junction (GEJ) adenocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Enhertu","company_name":"Washington D.C. Veterans Affairs Medical Center","drug_phase":"marketed","molecular_target":"DNA topoisomerase 1, Receptor tyrosine-protein kinase erbB-2","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"capecitabine","indication_name":"Treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeloda","generic_name":"capecitabine","company_name":"Cheplapharm","drug_phase":"marketed","molecular_target":"Thymidylate synthase","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":67,"revenue":null,"mechanism":"Xeloda works by inhibiting the enzyme thymidylate synthase, which is necessary for DNA synthesis in cancer cells."}],"pipeline":[],"offLabel":[],"totalMarketed":9,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04609813","title":"Esophageal cAncer Screening Trial","phase":"","overall_status":"COMPLETED","enrollment_count":14597,"lead_sponsor_name":"Changhai Hospital","has_results":false},{"nct_id":"NCT07260734","title":"AUGMENTED RESPONSE OF VOLATILE BIOMARKERS IN THE ASSESSMENT OF OESOPHAGOGASTRIC CANCER (AROMA2)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Imperial College London","has_results":false},{"nct_id":"NCT07431281","title":"Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":2130,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02872116","title":"Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2031,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT02426034","title":"A Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":2004,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT05334069","title":"Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT04290806","title":"Registry Platform Gastric/Esophageal Cancer (SAPHIR)","phase":"","overall_status":"RECRUITING","enrollment_count":1900,"lead_sponsor_name":"iOMEDICO AG","has_results":false},{"nct_id":"NCT04314401","title":"National Cancer Institute \"Cancer Moonshot Biobank\"","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1600,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04152499","title":"Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1410,"lead_sponsor_name":"Klus Pharma Inc.","has_results":false},{"nct_id":"NCT07144995","title":"MAIC of Fruquintinib Plus Paclitaxel Versus Ramucirumab Plus Paclitaxel in Advanced G/GEJ Adenocarcinoma","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1143,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04192734","title":"Retrospective Study of Ramucirumab and Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":1063,"lead_sponsor_name":"Hallym University Medical Center","has_results":false},{"nct_id":"NCT04389632","title":"A Study of Sigvotatug Vedotin in Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":1006,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT07149181","title":"Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as Postoperative Adjuvant Regimens in Patients With Resectable Gastric Cancer/Adenocarcinoma of the Esophagogastric Junction After Radical Surgery","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Liaoning Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT07132528","title":"Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as an Adjuvant Treatment After Radical Surgery for Patients With Resectable Adenocarcinoma of the Esophagogastric Junction of Gastric Cancer","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Liaoning Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT03777657","title":"Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":997,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT04895709","title":"A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":949,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT06131840","title":"A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":914,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT03170960","title":"Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":914,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT06764875","title":"A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":840,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07392892","title":"A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":840,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT06206733","title":"ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":780,"lead_sponsor_name":"AskGene Pharma, Inc.","has_results":false},{"nct_id":"NCT06841679","title":"Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":778,"lead_sponsor_name":"Beijing Biostar Pharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT06324357","title":"Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":768,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT03615326","title":"Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":738,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04140526","title":"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":733,"lead_sponsor_name":"OncoC4, Inc.","has_results":false},{"nct_id":"NCT04210115","title":"Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":703,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT07221149","title":"A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":690,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT03421288","title":"Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":677,"lead_sponsor_name":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","has_results":false},{"nct_id":"NCT02314117","title":"A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":645,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT05008783","title":"A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":610,"lead_sponsor_name":"Akeso","has_results":false},{"nct_id":"NCT02370498","title":"A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":592,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03504397","title":"A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":565,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT07284134","title":"JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":560,"lead_sponsor_name":"Shanghai Junshi Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT05052801","title":"Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":547,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT06649292","title":"SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":524,"lead_sponsor_name":"Shanghai Hengrui Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05111626","title":"Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":515,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT03653507","title":"A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":507,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT06901531","title":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT07161453","title":"Comparing the Efficacy and Safety of Different Postoperative Adjuvant Regimens in Patients With Resectable Adenocarcinoma of the Esophagogastric Junction Who Underwent Radical Surgery After Neoadjuvant Chemotherapy Combined With Immunotherapy and Achieved pCR in Postoperative Pathology","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Liaoning Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT03175224","title":"APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":497,"lead_sponsor_name":"Apollomics Inc.","has_results":false},{"nct_id":"NCT04435652","title":"A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer.","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":492,"lead_sponsor_name":"Qilu Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT04704934","title":"Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":490,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT06177041","title":"M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":486,"lead_sponsor_name":"FutureGen Biopharmaceutical (Beijing) Co., Ltd","has_results":false},{"nct_id":"NCT03802591","title":"A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":479,"lead_sponsor_name":"CStone Pharmaceuticals","has_results":false},{"nct_id":"NCT06238843","title":"A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":464,"lead_sponsor_name":"Innovent Biologics (Suzhou) Co. Ltd.","has_results":false},{"nct_id":"NCT02898077","title":"A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":440,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT07449780","title":"A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":422,"lead_sponsor_name":"Akeso","has_results":false},{"nct_id":"NCT07283939","title":"Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays","phase":"NA","overall_status":"RECRUITING","enrollment_count":420,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT05365581","title":"A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":398,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT07483554","title":"IBI343 in Combination Therapy for Advanced Malignant Solid Tumors","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":389,"lead_sponsor_name":"Innovent Biologics (Suzhou) Co. Ltd.","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}